Omega Funds
A Boston and Geneva venture firm that invests in medicines across oncology, immunology and rare disease. Its impact page lists cancer products it helped bring to patients, including the lung cancer drug Ibtrozi and the colorectal screening test Epi proColon.
Overview
Omega Funds has offices at 888 Boylston Street, Boston, and Place du Molard 7, Geneva, and invests through numbered funds (Omega Fund IV to VIII). Its site says it backs 'exceptional founders and entrepreneurs and impactful products and platforms' across oncology, immunology, rare diseases and precision medicine, and that it has 'helped bring 55 products to patients'. The firm invests from company creation through crossover rounds in the United States and Europe. Its impact page lists products from portfolio companies, including Ibtrozi (taletrectinib) for ROS1-positive non-small cell lung cancer, Imlygic (the first oncolytic viral therapy), Epi proColon (the first blood test for colorectal cancer screening) and Epi proLung (an mSHOX2 assay for suspected lung cancer).
Portfolio in OnCo (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Callio Therapeutics Seattle, WA, US | Startup | biotech | HER2-positive breast cancer | Series A 2025, $187M |
| Photys Therapeutics Boston, MA, US | Startup | biotech | Series A 2022, $75M |
Notes
top- Founding year not stated on the site and there is no Wikipedia article; omitted. The impact page lists products rather than company names, so portfolio examples are given by product.
Pages like this
not linked directly; found by shared links- CompanyMPM BioImpact
Shares Photys Therapeutics and the tag vc.
- CompanyLongwood Fund
Shares Photys Therapeutics and the tag vc.
- CompanyNovo Holdings
Shares Callio Therapeutics and the tag vc.
- CompanyJeito Capital
Shares Callio Therapeutics and the tag vc.
- CompanyFrazier Life Sciences
Shares Callio Therapeutics and the tag vc.